Perspective Therapeutics (CATX) Expected to Post Quarterly Earnings on Monday

Key Points

• Perspective Therapeutics is expected to report Q3 2026 results on November 9, with analysts forecasting a loss of $0.24 per share and revenue of approximately $0.06 million. The earnings call is scheduled for November 11 at 4:00 p.m. ET.
• In the previous quarter, the company reported a $0.22-per-share loss, beating estimates, while revenue of $0.08 million fell short of expectations. Analysts project losses of $0.98 per share for the current fiscal year and $1.09 per share next year.
• The stock opened at $1.15, near its one-year low of $1.06 and well below its 50-day and 200-day moving averages. Despite recent analyst downgrades and price-target cuts, the consensus rating remains “Moderate Buy”, with a $10.50 target price.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) will likely be issuing its Q3 2026 resultson Monday, November 9th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $0.06 million for the quarter. Parties can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:00 PM ET.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. On average, analysts expect Perspective Therapeutics to post ($0.98) EPS for the current fiscal year and ($1.09) EPS for the next fiscal year.

Perspective Therapeutics Price Performance

NYSEAMERICAN CATX opened at $1.15 on Monday. The firm's fifty day moving average price is $2.57 and its two-hundred day moving average price is $3.53. Perspective Therapeutics has a 1 year low of $1.06 and a 1 year high of $6.16.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. BTIG Research reiterated a "buy" rating on shares of Perspective Therapeutics in a research report on Monday, October 26th. Bank of America dropped their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, August 14th. Royal Bank Of Canada downgraded shares of Perspective Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their target price for the company from $14.00 to $4.00 in a research report on Monday, October 26th. Piper Sandler decreased their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating on the stock in a report on Tuesday, August 11th. Finally, Wedbush reiterated an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, September 15th. Nine investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.50.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company's platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company's lead programs include VMT-α-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.